<i>Ultra low dose oral menopausal hormone therapy – unrealized dream or reality?</i>

Grzegorz Stachowiak; Tomasz Pertyński

Abstract

4/2011 vol. 10

Review paper

Ultra low dose oral menopausal hormone therapy – unrealized dream or reality?

Grzegorz Stachowiak

,

Tomasz Pertyński

Przegląd Menopauzalny 2011; 4: 271–274

Online publish date: 2011/08/30

View full text

AMA

Stachowiak G, Pertyński T. Ultra low dose oral menopausal hormone therapy – unrealized dream or reality?. Menopause Review/Przegląd Menopauzalny. 2011;10(4):271-274.

APA

Stachowiak, G., & Pertyński, T. (2011). Ultra low dose oral menopausal hormone therapy – unrealized dream or reality?. Menopause Review/Przegląd Menopauzalny, 10(4), 271-274.

Chicago

Stachowiak, Grzegorz, and Tomasz Pertyński. 2011. "Ultra low dose oral menopausal hormone therapy – unrealized dream or reality?". Menopause Review/Przegląd Menopauzalny 10 (4): 271-274.

Harvard

Stachowiak, G., and Pertyński, T. (2011). Ultra low dose oral menopausal hormone therapy – unrealized dream or reality?. Menopause Review/Przegląd Menopauzalny, 10(4), pp.271-274.

MLA

Stachowiak, Grzegorz et al. "Ultra low dose oral menopausal hormone therapy – unrealized dream or reality?." Menopause Review/Przegląd Menopauzalny, vol. 10, no. 4, 2011, pp. 271-274.

Vancouver

Stachowiak G, Pertyński T. Ultra low dose oral menopausal hormone therapy – unrealized dream or reality?. Menopause Review/Przegląd Menopauzalny. 2011;10(4):271-274.

Reduction of estrogen and progestogen doses is one of the main trends in oral menopausal hormone therapy (MHT). Studies on ultra low oral MHT, composed of 0,5 mg estradiol plus reduced doses of various progestoagens (e.g. norethisterone acetate, dydrogesterone), revealed both its high safety profile as well as therapeutic efficacy in alleviating of numerous aliments of the menopausal period.